உயிர் பாதை ஹோல்டிங்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உயிர் பாதை ஹோல்டிங்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உயிர் பாதை ஹோல்டிங்ஸ் Today - Breaking & Trending Today

Bio-Path: Q2 Earnings Snapshot

Bio-Path: Q2 Earnings Snapshot
theparisnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theparisnews.com Daily Mail and Mail on Sunday newspapers.

United States , Path Holdings Inc , Bio Path Holdings , ஒன்றுபட்டது மாநிலங்களில் , பாதை ஹோல்டிங்ஸ் இன்க் , உயிர் பாதை ஹோல்டிங்ஸ் ,

Bio-Path: Q1 Earnings Snapshot

Bio-Path: Q1 Earnings Snapshot
theparisnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theparisnews.com Daily Mail and Mail on Sunday newspapers.

United States , Path Holdings Inc , Bio Path Holdings , ஒன்றுபட்டது மாநிலங்களில் , பாதை ஹோல்டிங்ஸ் இன்க் , உயிர் பாதை ஹோல்டிங்ஸ் ,

Bio-Path Holdings Reports First Quarter 2021 Financial Results


Bio-Path Holdings Reports First Quarter 2021 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET
HOUSTON, May 14, 2021 (GLOBE NEWSWIRE) Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize
® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent corporate developments.
“The start of 2021 has been marked by substantial progress across our portfolio of targeted nucleic cancer drugs which included both presented and published data in support of our DNAbilize platform,” stated Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We recently announced the successful completion of the safety run-in of Stage 2 of the Phase 2 clinical study of prexigebersen for the treatment of acute myeloid leukemia (AML) in combinat ....

United States , Peter Nielsen , Doug Morris , Exchange Commission , Path Holdings , Path Holdings Inc , Trademark Office , American Association For Cancer Research , Stern Investor Relations Inc , Conference Call , Held Today , Bio Path Holdings , Chief Executive Officer , Cancer Research , Completed Safety Cohort , Triple Combination , Grant Related , United States Patent , First Quarter Ended March , Webcast Information , Annual Report , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , பீட்டர் நீல்சன் , டக் மோரிஸ் , பரிமாற்றம் தரகு ,